Positive Topline Ph 2 Results Announced for mRNA Immunotherapy BNT111 in Patients with Advanced Melanoma August 6, 2024
11.1 Month Increase in OS in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 in OVATION 2 Ph 2 trial Announced August 6, 2024
FAILED TRIAL: Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies show primary endpoint of OS improvement not achieved August 6, 2024
Scemblix® Granted FDA Priority Review For The Treatment Of Adults With Newly Diagnosed CML based on ASC4FIRST Ph 3 study data August 6, 2024
IND Application filed for First in Class Senolytic Immunotherapy SenoVax™ for Treatment of Advanced Lung Cancer August 6, 2024
FDA Clears IND Application for UB-VV111, a CD19 Directed in situ CAR-T for Heme Malignancies August 6, 2024
FDA Fast Track Designation Granted to Soquelitinib for Treatment of Patients with R/R PTCL August 6, 2024
FDA grants Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer August 6, 2024
FDA expands Jemperli (dostarlimab) + chemo approval to all adult patients with primary advanced or recurrent endometrial cancer with demonstrated OS benefit August 6, 2024
